A Phase 2 Study (2-Stage, 2-Cohort) Of The Oral Parp Inhibitor Talazoparib (Bmn 673) In Patients With Germline Brca Mutation And Locally Advanced And/Or Metastatic Breast Cancer (Abrazo).
JOURNAL OF CLINICAL ONCOLOGY（2015）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要